“Global Huntington’s Disease Treatment to reach a market value of USD 805.1 Million by 2031 growing at a CAGR of 9.0%”
The Global Huntington's Disease Treatment Market size is expected to reach $805.1 million by 2031, rising at a market growth of 9.0% CAGR during the forecast period.
The Asia-Pacific region's nations are investing in expanding and modernizing its hospitals, clinics, and specialized treatment facilities. Better facilities and access to healthcare enable HD patients to receive sophisticated treatment choices, interdisciplinary care, and early diagnosis. Consequently, the Asia pacific region would acquire nearly 25% of the total market share by 2031. Genetic diversity within the Asia Pacific region provides unique opportunities for studying Huntington’s Disease genetics, disease variants, and population-specific factors influencing disease progression.
Huntington’s disease is caused by a mutation in the HTT gene, which produces an abnormal form of the huntingtin protein. Moreover, RNA interference (RNAi) and antisense oligonucleotides (ASOs) are biotechnological approaches that can reduce the expression of the mutant HTT gene. Moreover, RNA interference (RNAi) and antisense oligonucleotides (ASOs) are biotechnological approaches that can reduce the expression of the mutant HTT gene. Additionally, Healthcare expenditure encompasses funding allocated to biomedical research, including neurodegenerative diseases like Huntington’s disease. Furthermore, investments in healthcare infrastructure, such as specialized clinics, research centers, and laboratory facilities, are essential for advancing HD research and treatment. Therefore, rising healthcare expenditures and investments are propelling the market’s growth.
However, A poisonous mutant huntingtin protein (mHTT) results from an HTT gene mutation that causes HD. This genetic mutation leads to neuronal dysfunction and eventual neurodegeneration. Moreover, the clinical manifestations of HD vary widely among individuals, both in terms of symptom onset and progression. Thus, complex disease pathophysiology is hampering the growth of the market.
The pandemic led to the suspension or delay of many clinical trials for Huntington’s Disease due to lockdowns, travel restrictions, and the reallocation of healthcare resources to address COVID-19. In addition, the global supply chain disruptions caused by the pandemic affected the availability of medications and medical supplies for HD patients. Thus, the COVID-19 pandemic had a negative impact on the market.
Based on drug type, the Huntington's Disease Treatment Market is divided into approved drugs and offlabel drugs. In 2023, the offlable drugs segment acquired 15.3% revenue share in the Huntington's Disease Treatment Market. Off-label drugs may offer potential benefits in managing specific symptoms of Huntington’s Disease, such as psychiatric symptoms (e.g., depression, anxiety), irritability, and cognitive impairment. Healthcare providers may explore off-label options to alleviate these challenging symptoms that significantly impact patient quality of life.
On the basis of distribution channel, the Huntington's Disease Treatment Market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. In 2023, the drug stores & retail pharmacies segment attained 32.7% revenue share in the Huntington's Disease Treatment Market. Retail pharmacies stock a variety of medications used to manage symptoms associated with Huntington’s Disease, including medications for chorea (involuntary movements), psychiatric symptoms (e.g., depression, anxiety), and cognitive impairments.
By age, the Huntington's Disease Treatment Market is bifurcated into below 50 years and above 50 years. The above 50 segment held 43.3% revenue share in the Huntington's Disease Treatment Market in 2023. Huntington’s Disease can present with subtle or atypical symptoms in older adults, leading to delays in diagnosis. As awareness and diagnostic capabilities improve, more individuals above 50 years old may receive a diagnosis of HD, prompting the initiation of treatment and management strategies to address symptoms and optimize quality of life.
Free Valuable Insights: Global Huntington's Disease Treatment Market size to reach USD 805.1 Million by 2031
Region-wise, the Huntington's Disease Treatment Market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region witnessed 42% revenue share in the Huntington's Disease Treatment Market in 2023. North America has a relatively higher Huntington’s Disease prevalence than other regions. The disease is more commonly diagnosed among populations of European descent, which are prominent in North America. Also, the region is a global leader in biomedical research and pharmaceutical innovation.
| Report Attribute | Details |
|---|---|
| Market size value in 2023 | USD 407.8 Million |
| Market size forecast in 2031 | USD 805.1 Million |
| Base Year | 2023 |
| Historical Period | 2020 to 2022 |
| Forecast Period | 2024 to 2031 |
| Revenue Growth Rate | CAGR of 9.0% from 2024 to 2031 |
| Number of Pages | 266 |
| Number of Tables | 410 |
| Report coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Porter’s 5 Forces Analysis, Company Profiling, Companies Strategic Developments, SWOT Analysis, Winning Imperatives |
| Segments covered | Drug Type, Distribution Channel, Age, Region |
| Country scope |
|
| Companies Included | Bausch Health Companies, Inc., Teva Pharmaceutical Industries Ltd., Camber Pharmaceuticals, Inc. (Hetero Labs Limited), Hikma, Pharmaceuticals PLC, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Neurocrine Biosciences Inc., Pfizer, Inc. and F. Hoffmann-La Roche Ltd. |
By Drug Type
By Distribution Channel
By Age
By Geography
This Market size is expected to reach $805.1 million by 2031.
Advancements in genetic research and biotechnology are driving the Market in coming years, however,Complex disease pathophysiology restraints the growth of the Market.
Bausch Health Companies, Inc., Teva Pharmaceutical Industries Ltd., Camber Pharmaceuticals, Inc. (Hetero Labs Limited), Hikma, Pharmaceuticals PLC, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Neurocrine Biosciences Inc., Pfizer, Inc. and F. Hoffmann-La Roche Ltd.
The expected CAGR of this Market is 3.4% from 2023 to 2031.
The Hospital Pharmacies segment led the by Distribution Channel in 2023; thereby, achieving a market value of $447.2 Million by 2031.
The North America region dominated the by Region in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $327 Million by 2031.
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 